Clinical Trials
19 trialsNCT06051695 2026-05-26
EVEREST-2
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT01950572 2026-05-11
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Recruiting
NCT01851395 2026-05-05
Rapid Autopsy and Procurement of Cancer Tissue
National Institutes of Health Clinical Center (CC)
Terminated
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT00242723 2026-05-01
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
National Institutes of Health Clinical Center (CC)
Recruiting
NCT04491942 2026-04-13
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT06996249 2026-03-03
DuTOC
Dutch Society of Physicians for Pulmonology and Tuberculosis
Recruiting
NCT06885697 2026-02-17
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06466187 2026-01-12
A Study of SGN-MesoC2 in Advanced Solid Tumors
Seagen Inc.
Phase 1 Active not recruiting
NCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT01385722 2025-12-26
Molecular Analysis of Thoracic Malignancies
Stanford University
Enrolling by invitation
NCT03556228 2025-12-11
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
Phase 1/2 Recruiting
NCT04115254 2025-11-13
Stereotactic Magnetic Resonance Guided Radiation Therapy
Dana-Farber Cancer Institute
Phase NA Recruiting
NCT02414269 2025-10-08
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT02214134 2025-08-17
SPECTAlung
European Organisation for Research and Treatment of Cancer - EORTC
Completed
NCT02903914 2025-08-05
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
Phase 1 Completed
NCT02078700 2025-06-25
Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
Azienda USL Reggio Emilia - IRCCS
Phase 2 Completed
NCT05944237 2025-06-08
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
Phase 1/2 Recruiting